SkinBioTherapeutics (LON:SBTX) Trading 9% Higher – What’s Next?

SkinBioTherapeutics plc (LON:SBTX) shares shot up 9% during mid-day trading on Friday . The company traded as high as GBX 11 and last traded at GBX 10.90. 240,484 shares were traded during trading, a decline of 95% from the average session volume of 5,237,935 shares. The stock had previously closed at GBX 10.

SkinBioTherapeutics Stock Performance

The firm has a 50-day moving average of GBX 15.05 and a 200 day moving average of GBX 15.18. The stock has a market capitalization of £26.27 million, a P/E ratio of -32.70 and a beta of 0.47. The company has a quick ratio of 10.01, a current ratio of 4.84 and a debt-to-equity ratio of 10.55.

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.